Yükleniyor... / Loading...
This observational safety study monitors the real-world use of avacopan and other standard treatments in patients with ANCA-associated vasculitis. It enrolls patients aged 18 and over with active, severe disease who have started or are planned to start avacopan, cyclophosphamide, or rituximab. It is a study without an assigned phase and is currently recruiting.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Diagnosis of AAV (MPA or GPA), as determined by the Investigator according to their usual practice. * Active, severe AAV at the time of commencing avacopan or non-avacopan SoC induction therapy, in the opinion of the Investigator. * Age ≥18 years of either sex. * Has provided written informed consent. * Has commenced within the previous 6 months, or is planned to commence avacopan, cyclophosphamide or rituximab for the treatment of severe, active AAV outside of an interventional clinical study. Exclusion Criteria: • Concurrent participation in an interventional study, unless prospectively discussed and agreed with the Medical Monitor.